Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 5/20 | 0.42 |
| ▸ | ADORA3 | P0DMS8 | 5/20 | 0.42 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.42 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20064696 | 0.87 | HPGD (0.48) | ADORA2AADORA3ADORA1ADORA2BMAPT | |
| SCHEMBL20064748 | 0.86 | DPP4 (0.43) | MAPTTP53KDM4EALDH1A1 | |
| SCHEMBL18198351 | 0.85 | MCL1 (0.36) | MAPTTP53KDM4EALDH1A1HSD17B10 | |
| SCHEMBL20064800 | 0.84 | KDM4E (0.35) | MAPTTP53KDM4EALDH1A1HSD17B10 | |
| SCHEMBL18198326 | 0.84 | KDM4E (0.36) | MAPTKDM4EALDH1A1HSD17B10POLB | |
| SCHEMBL20064752 | 0.82 | ALDH1A1 (0.38) | MAPTTP53KDM4EALDH1A1 | |
| SCHEMBL20064763 | 0.82 | ABCB1 (0.39) | MAPTTP53KDM4EALDH1A1HSD17B10 | |
| SCHEMBL20064794 | 0.81 | MET (0.42) | — | |
| SCHEMBL20065181 | 0.80 | ADORA2A (0.35) | ADORA2AADORA3ADORA1ADORA2BMAPT | |
| SCHEMBL20065179 | 0.80 | TSPO (0.36) | ADORA2AADORA3ADORA1ADORA2BMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3288942-B1 | RSV ANTIVIRAL PYRAZOLO- AND TRIAZOLO-PYRIMIDINE COMPOUNDS | JANSSEN SCIENCES IRELAND UNLIMITED CO (IE) | 2021-10-27 | — | — | EP | disclosed |
| US-11084826-B2 | RSV antiviral pyrazolo- and triazolo-pyrimidine compounds | Janssen Sciences Ireland Unlimited Company (IE) | 2021-08-10 | — | — | US | disclosed |
| US-20200223855-A1 | RSV ANTIVIRAL PYRAZOLO- AND TRIAZOLO-PYRIMIDINE COMPOUNDS | JANSSEN SCIENCES IRELAND UNLIMITED CO (IE) | 2020-07-16 | — | — | US | disclosed |
| US-20190248793-A1 | RSV ANTIVIRAL PYRAZOLO- AND TRIAZOLO-PYRIMIDINE COMPOUNDS | Janssen Sciences Ireland Unlimited Company (IE) | 2019-08-15 | — | — | US | disclosed |
| US-10208048-B2 | RSV antiviral pyrazolo- and triazolo-pyrimidine compounds | JANSSEN SCIENCES IRELAND UC (IE) | 2019-02-19 | — | — | US | disclosed |
| US-20180105529-A1 | RSV ANTIVIRAL PYRAZOLO- AND TRIAZOLO-PYRIMIDINE COMPOUNDS | JANSSEN SCIENCES IRELAND UC (IE) | 2018-04-19 | — | — | US | disclosed |
| US-20180105529-A1 | RSV ANTIVIRAL PYRAZOLO- AND TRIAZOLO-PYRIMIDINE COMPOUNDS | JANSSEN SCIENCES IRELAND UC (IE) | 2018-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10208048-B2 | RSV antiviral pyrazolo- and triazolo-pyrimidine compounds | ZC3HAV1, MAVS, TYMP | ADORA2A 1067/4885ADORA3 578/4885ADORA1 733/4885 |
| US-20200223855-A1 | RSV ANTIVIRAL PYRAZOLO- AND TRIAZOLO-PYRIMIDINE COMPOUNDS | ZC3HAV1, MAVS, TYMP | ADORA2A 1067/4885ADORA3 578/4885ADORA1 733/4885 |
| US-11084826-B2 | RSV antiviral pyrazolo- and triazolo-pyrimidine compounds | ZC3HAV1, MAVS, TYMP | ADORA2A 1067/4885ADORA3 578/4885ADORA1 733/4885 |
| US-20180105529-A1 | RSV ANTIVIRAL PYRAZOLO- AND TRIAZOLO-PYRIMIDINE COMPOUNDS | ZC3HAV1, MAVS, TYMP | ADORA2A 1067/4885ADORA3 578/4885ADORA1 733/4885 |
| US-20190248793-A1 | RSV ANTIVIRAL PYRAZOLO- AND TRIAZOLO-PYRIMIDINE COMPOUNDS | ZC3HAV1, MAVS, TYMP | ADORA2A 1067/4885ADORA3 578/4885ADORA1 733/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.